Noan (Diazepam)

Diazepam binds to a specific site on the GABA‑A receptor complex, acting as a positive allosteric modulator. This enhances the inhibitory action of GABA, increasing chloride influx into neurons, which hyperpolarises the cell membrane and reduces neuronal firing throughout the central nervous system.

The appropriate dose of Noan is determined by the prescribing clinician based on the patient’s age, clinical condition, response to therapy and any concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions.

Diazepam is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be used during pregnancy only if the potential benefit justifies the risk. Breastfeeding is not recommended because diazepam passes into milk and may affect the infant.

To request Noan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Noan (diazepam) has a relatively long half‑life compared with agents such as lorazepam or alprazolam, providing smoother plasma levels but a higher potential for accumulation. Its broad indication profile makes it useful for both anxiety and seizure control, whereas some alternatives are more selective for one therapeutic area.

Store Noan at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discoloured.

Noan is supplied as an oral tablet and should be taken by mouth with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels.

The most serious risks include respiratory depression, especially when combined with other CNS depressants, severe hypotension, paradoxical reactions such as agitation or aggression, development of physical dependence, and the potential for withdrawal seizures if the medication is stopped abruptly.

Noan is contraindicated in patients with acute narrow‑angle glaucoma, severe respiratory insufficiency, myasthenia gravis, severe hepatic impairment, and in individuals who have shown hypersensitivity to diazepam or any benzodiazepine component.